L'Oréal invests in a new startup again

Through L'Oréal Bold, its venture capital fund dedicated to startups, it has acquired a minority stake in Timeline

18 of January of 2024
Timeline Mitopure
Timeline Mitopure

L'Oréal completes its third startup investment so far in 2024. Through its venture capital fund dedicated exclusively to startup investments, it has acquired a minority stake in Timeline.

Timeline is a Swiss biotech company that has developed a patented molecule that, as they explain, helps to rejuvenate and recycle the mitochondria of the ageing cell. The company specialises in the development of ingredients, actives and molecules focused on longevity.

Mitopure, the unique molecule developed by the Swiss biotech company, is currently being incorporated into food supplements and skin care products. 

The amount of the deal has not been disclosed by either party. The deal will enable Timeline to further develop its technology, expand its business and pave the way for future collaborations and partnerships with L'Oréal and companies within the French cosmetics giant's group.

Barbara Lavernos, L'Oréal Groupe's deputy CEO and general manager of research, innovation and technology points out that what Timeline does is part of a new dimension within the field of beauty and cosmetics: "Longevity adds a new dimension to beauty by preventing, correcting and even reversing the ageing cycle of skin, scalp and hair. We are delighted with our investment in Timeline, which should enable us to translate the key features of longevity into skin health and beauty."

Patrick Aebischer, co-founder and chairman of Timeline, added: "This strategic collaboration reflects the innovative multi-dimensional approach we have always believed is necessary to make significant advances in longevity and health."